Find the Perfect Plan for Your Investment Journey
Last Price
52 Week Range
$7.55 - $18.51
Next Earnings Date
May 08 2025
Next Earnings Date
May 08 2025
Last Price
Market Cap | $1.39B |
EV | $1.14B |
Shares Outstanding | 106.18M |
Beta | 0.94 |
Analyst Rating | BUY |
Analyst Target Price | $31.60 |
P/E 2025E | - |
P/Revenue 2025E | 16.72x |
Revenue | 153.00% |
EPS | - |
Operating Cash Flow | - |
Free Cash Flow | - |
Revenue | 97.60% |
EPS | 44.20% |
Operating Cash Flow | - |
Free Cash Flow | 82.00% |
Gross Margin 2025E | - |
Net Profit Margin 2025E | -167.45% |
ROE 2025E | - |
ROCE 2024 | 3.28% |
DPS 2025E | - |
Payout Ratio 2025E | - |
Div. Yield 2025E | - |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
ARS Pharmaceuticals, Inc.
SPRY
Sector
Healthcare
Industry
Biotechnology
CEO
Lowenthal, Richard
Employees
158
Website
ars-pharma.comIPO Date
2020-12-04
Headquarters
11682 El Camino Real, Suite 120, San Diego, California, 92130, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved